Elite in Nasal Polyps

Shigeharu Fujieda

Head And Neck Surgery, 
JP 
Elite in Nasal Polyps
Head And Neck Surgery, 
JP 
OverviewLocationsClinical Research

Overview

Shigeharu Fujieda practices in Japan. Fujieda is rated as an Elite expert by MediFind in the treatment of Nasal Polyps. Their top areas of expertise are Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Nasal Polyps, Allergic Rhinitis, and Sinusitis.

Their clinical research consists of co-authoring 176 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 43 articles and participated in 1 clinical trial in the study of Nasal Polyps.

Locations

Head And Neck Surgery, Japan
Other Locations
Head And Neck Surgery, 23 Shimoaizuki, Eiheiji, Matsuoka, 9101193, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
A Randomised, Double-blind, Placebo Controlled, Parallel Group Phase III Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) / Eosinophilic Chronic Rhinosinusitis (ECRS) MERIT: Mepolizumab in Eosinophilic Chronic RhinosinusITis Study
Enrollment Status: Completed
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: Mepolizumab, Standard of Care
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

176 Total Publications

The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps.
The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps.
Journal: Allergy and asthma proceedings
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fujieda's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile